Juniper Pharmaceuticals Inc. (JNP) Given $9.98 Average Price Target by Brokerages
Shares of Juniper Pharmaceuticals Inc. (NASDAQ:JNP) have received a consensus broker rating score of 2.33 (Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company. Juniper Pharmaceuticals’ rating score has declined by 133% in the last three months as a result of a number of analysts’ ratings changes.
Analysts have set a 1-year consensus price target of $9.98 for the company and are expecting that the company will post ($0.13) EPS for the current quarter, according to Zacks. Zacks has also given Juniper Pharmaceuticals an industry rank of 113 out of 265 based on the ratings given to its competitors.
JNP has been the subject of a number of recent analyst reports. Zacks Investment Research cut Juniper Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 21st. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Juniper Pharmaceuticals in a report on Tuesday, July 5th. Roth Capital restated a “buy” rating on shares of Juniper Pharmaceuticals in a report on Tuesday, July 12th. Northland Securities cut Juniper Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, August 18th. Finally, TheStreet cut Juniper Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, September 12th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/juniper-pharmaceuticals-inc-jnp-given-9-98-average-price-target-by-brokerages.html
In related news, insider Alicia Secor purchased 5,000 shares of Juniper Pharmaceuticals stock in a transaction dated Thursday, August 25th. The stock was purchased at an average cost of $5.75 per share, with a total value of $28,750.00. Following the transaction, the insider now owns 5,000 shares in the company, valued at approximately $28,750. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director James A. Geraghty purchased 7,000 shares of Juniper Pharmaceuticals stock in a transaction dated Tuesday, August 23rd. The stock was bought at an average cost of $5.96 per share, with a total value of $41,720.00. Following the completion of the transaction, the director now owns 58,216 shares in the company, valued at approximately $346,967.36. The disclosure for this purchase can be found here. 11.60% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wedge Capital Management L L P NC raised its position in Juniper Pharmaceuticals by 28.6% in the second quarter. Wedge Capital Management L L P NC now owns 72,400 shares of the specialty pharmaceutical company’s stock valued at $508,000 after buying an additional 16,100 shares during the last quarter. Eagle Global Advisors LLC acquired a new position in shares of Juniper Pharmaceuticals during the second quarter valued at about $241,000. Bridgeway Capital Management Inc. raised its position in shares of Juniper Pharmaceuticals by 27.0% in the second quarter. Bridgeway Capital Management Inc. now owns 180,200 shares of the specialty pharmaceutical company’s stock valued at $1,263,000 after buying an additional 38,350 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of Juniper Pharmaceuticals by 14.8% in the second quarter. BlackRock Fund Advisors now owns 28,292 shares of the specialty pharmaceutical company’s stock valued at $198,000 after buying an additional 3,639 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Juniper Pharmaceuticals by 0.6% in the second quarter. Vanguard Group Inc. now owns 435,627 shares of the specialty pharmaceutical company’s stock valued at $3,054,000 after buying an additional 2,588 shares in the last quarter. 33.61% of the stock is owned by hedge funds and other institutional investors.
Shares of Juniper Pharmaceuticals (NASDAQ:JNP) traded down 0.92% during trading on Monday, hitting $5.40. The stock had a trading volume of 1,110 shares. The stock has a 50-day moving average price of $5.68 and a 200 day moving average price of $6.74. Juniper Pharmaceuticals has a 12 month low of $4.30 and a 12 month high of $12.75. The company’s market cap is $58.55 million.
Juniper Pharmaceuticals (NASDAQ:JNP) last announced its earnings results on Thursday, August 4th. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by $0.08. Juniper Pharmaceuticals had a negative return on equity of 6.39% and a negative net margin of 5.81%. Equities analysts expect that Juniper Pharmaceuticals will post ($0.39) EPS for the current fiscal year.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc, formerly Columbia Laboratories, Inc, is a women’s health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women’s health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.